HOLOCLAR

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug HOLOCLAR contains one active pharmaceutical ingredient (API):

1	Autologous human corneal epithelial cells UNII RH2309K129 - AUTOLOGOUS HUMAN LIMBAL STEM CELL
	The mechanism of action of limbal stem cells implantation is the replacement of corneal epithelium and lost limbal stem cells in patients in which the limbus has been destroyed by ocular burns. During the corneal repair process, the administered stem cells are intended to partially multiply, differentiate and migrate to regenerate corneal epithelium, as well as maintaining a reservoir of stem cells that can continually regenerate the corneal epithelium.
	Read more about Limbal stem cells

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HOLOCLAR Living tissue equivalent	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01XA19		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1677775
ES	Centro de información online de medicamentos de la AEMPS	114987001
FR	Base de données publique des médicaments	62223501
GB	Medicines & Healthcare Products Regulatory Agency	348816
IT	Agenzia del Farmaco	043909011
LT	Valstybinė vaistų kontrolės tarnyba	1075840
PL	Rejestru Produktów Leczniczych	100339008